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Abst rac t
Introduction: The incidence of metabolic syndrome is estimated at 15–24% in the general population and at 30–50% 
in patients with psoriasis. A probable cause of the described correlation is a constant release in chronic dermatosis 
of proinflammatory cytokines and their influence on individual systems and organs.
Aim: Assessment of the concentration of the proinflammatory cytokines (IL-12, IL-23, IL-17 and TNF-α) in blood 
serum and their correlation with the intensity of skin lesions, the presence of psoriatic arthritis and the risk of 
development of obesity and metabolic syndrome.
Material and methods: The concentrations of subunit p70 IL-12, IL-17 and IL-23, and TNF-α in subjects with psoriasis 
and metabolic syndrome were determined.
Results: The level of the studied cytokines, IL-17, IL-23 and TNF-α was higher in patients diagnosed with psoriasis. 
Higher levels of IL-17, IL-23 and TNF-α were observed in patients with metabolic syndrome accompanying psoria-
sis. A higher level of IL-17 and IL-23 was found in sera of patients with psoriatic arthritis in comparison to normal 
psoriasis.
Conclusions: In the study, a higher level of IL-17 and IL-23 was also shown in patients with psoriatic arthritis in 
comparison to patients with normal psoriasis. The effectiveness of anti-IL12/23 drugs in psoriatic arthritis is a con-
firmation of the obtained results of the studies. Additionally, the increased level of IL-17, both in patients with 
metabolic syndrome and with psoriasis, could indirectly indicate an increased cardiovascular risk in patients with 
affected joints in comparison to psoriasis affecting only the skin.
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Introduction
Psoriasis (PsO) is a chronic inflammatory disease 
with immunologic etiology, depending mainly on T lym-
phocytes and dendritic cells [1]. Many previous studies 
have demonstrated a more frequent coincidence of der-
matosis with other systemic diseases, such as metabolic 
syndrome (MS), cancers, ischemic heart disease, chronic 
obstructive pulmonary disease, inflammatory bowel dis-
eases, depression, and osteoporosis [2–4]. The incidence 
of metabolic syndrome is estimated at 15–24% in the 
general population and at 30–50% in patients with pso-
riasis [5]. A probable cause of the described correlation is 
a constant release in chronic dermatosis, over the years, 
of proinflammatory cytokines, mainly tumor necrosis fac-
tor α (TNF-α) and interleukin (IL)-6, and their influence 
on individual systems and organs [6]. It is known that 
mainly IL-12 and IL-23, released by dendritic cells, are im-
portant in the immune etiology of psoriasis. They activate 
Th1 and Th2 to produce many cytokines: IL-17, interferon 
(IFN)-γ, TNF-α and IL-22, which, by direct stimulation of 
keratinocytes, cause the formation of psoriatic lesions 
[1]. The described etiology is confirmed by the results of 
therapies with antibodies against the above inflamma-
tory molecules, commonly used in the psoriasis treat-
ment. The results of previous studies unambiguously 
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confirm the correlation between the TNF-α in serum and 
the intensity of skin lesions. The results of studies on the 
concentration of IL-17 are IL-23 are ambiguous – some of 
them indicate a strong correlation between the severity 
of the disease and the level of circulating interleukins, 
however, there are reports where the evaluated cytokines 
were indeterminable despite the advancement of the dis-
ease [7].
In recent years, the influence of methotrexate on 
the reduction of the risk of cardiovascular diseases has 
been described many times. The mechanism of this phe-
nomenon is not known [8]. Currently, the studies are 
conducted to explain the influence of biological drugs 
on the development of the individual components of the 
metabolic syndrome. There are many reports on the re-
duction of insulin resistance, hyperlipidemia and waist 
circumference in patients receiving anti-TNF [9, 10]. How-
ever, experimental studies on mice showed that IL-17 can 
be a negative regulator of adipogenesis and glucose level 
and hence it delays the development of obesity [11]. Sub-
sequent studies are necessary to indicate the profile of 
inflammatory cytokines in patients with psoriasis accom-
panied by metabolic syndrome, in order to evaluate the 
potential influence of biological drugs on the reduction 
of the incidence of complications in the form of diabetes, 
ischemic heart disease, hypertension or hypercholester-
olemia. 
Aim 
Considering the most widely described influence of 
IL-12, IL-23, IL-17 and TNF-α on the formation of psori-
atic plaques, an attempt was made to assess the con-
centration of the above proinflammatory cytokines in 
blood serum and their correlation with the intensity of 
skin lesions, the presence of psoriatic arthritis and the 
risk of development of obesity and metabolic syndrome. 
The association between levels of cytokines in psoria-
sis and presence of metabolic syndrome could imply the 
treatment, especially therapy that is correlated with IL-17, 
IL-23 or TNF-α.
Material and methods
For this study, 60 patients over 18 years of age were 
included (24 females and 36 males), diagnosed and treat-
ed for severe psoriasis (PASI, BSA > 10) in the Dermatol-
ogy Clinic of the Jagiellonian University Medical College. 
Control groups comprised 15 subjects diagnosed with 
metabolic syndrome and 15 healthy voluntary subjects. In 
both groups, the exclusion criteria were acute and chron-
ic inflammatory diseases with the exception of diabetes, 
hypertension and dyslipidemia.
For testing, venous blood (5 ml) was collected after 
the night rest. The concentrations of subunit p70 IL-12, 
IL-17 and IL-23 and TNF-α in subjects’ sera were deter-
mined by Quantikine test with enhanced sensitivity, with 
the ELISA method. The expected values were: IL-12 ND 
– 3.58 pg/ml; IL-17 below 31.2 pg/ml; IL-23 ND – 40.5 pg/
ml; and TNF-α 0.550 – 2.816 pg/ml. The advancement of 
psoriasis was evaluated with PASI and BSA scales. The 
PASI scale (psoriasis area and severity index) combines 
three physical features: (erythema, desquamation and 
induration), as three separate parameters, calculated 
for every part of the body separately, considering their 
intensity and the percentage of the affected area. Psori-
atic arthritis was diagnosed based on the Caspar criteria 
(2006). Metabolic syndrome was diagnosed based on the 
presence of revised NCEP-ATP III criteria for metabolic 
syndrome, according to ANA/NHBLI. 
A multivariable logistic regression analysis was per-
formed to identify the factors that were independently 
associated with levels of Il-17, IL-23 and TNF-α. Data were 
summarized descriptively and differences in dichoto-
mous and continuous variables were examined between 
patients with and without psoriasis and metabolic syn-
drome. All data were analyzed by Statistica using Mann-
Whitney and Spearman’s rho. A p-value ≤ 0.05 was con-
sidered significant.
For the above studies, consent of the Bioethics Com-
mittee of the Jagiellonian University was obtained.
Results
The IL-12 level in all the subjects was indeterminable 
(< 0.78 pg/ml). The level of IL-23 and TNF-α was higher in 
patients diagnosed with psoriasis in comparison to the 
control group (serum concentration mean values of IL-23 
were: 8.33 ±7.83 vs. 3.13 ±3.11 (p < 0.05) and TNF-α 1.98 
±1.50 vs. 1.13 ±0.42 (p < 0.05). The concentration of IL-17 
in the study group (2.56 ±3.15), compared to the control 
group (2.07 ±4.23) was higher, however the results were 
not statistically significant (p = 0.52) (Figure 1, Table 1). 
Higher levels of IL-17, IL-23 and TNF-α were observed in 
patients with metabolic syndrome accompanying pso-
riasis in comparison to patients with chronic derma-
tosis without the features of this syndrome, however 
they were significantly different only between the IL-17 
groups: IL-17 4.05 vs. 2.09; p < 0.05; IL-23 8.12 vs. 8.25; 
p = 0.41; TNF-α 2.42 vs. 1.83; p = 0.42 (Figure 2, Table 2). 
There was no significant change in the serum concentra-
tion of all cytokines in the control group in patients with 
metabolic syndrome in comparison to subjects without 
the syndrome (TNF-α 1.21 ±0.43; vs. 0.94 ±1.43; p = 0.14; 
IL-23 2.77 ±1.85 vs. 4.52 ±4.76; p = 0.19; IL-17 2.20 ±1.55 vs. 
2.03 ±1.57; p = 0.77). No positive correlation was found 
between PASI, BSA and the level of cytokines (IL-17, IL-23, 
TNF-α). 
Among the patients with psoriasis and psoriatic ar-
thritis, no correlation was observed between the level of 
IL-17, IL-23, TNF-α and BMI (r = 0.03, p = 0.79; r = –0.13, 
p = 0.32; r = 0.10, p = 0.44). The observations between 
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Figure 1. Serum concentration of IL-17, IL-23 and TNF-α in 
the study and control groups. Mann-Whitney U test was 
performed to evaluate differences between the control and 
study groups. Median, lower and upper quartiles 25–75%, 
min.–max. of range are presented
Table 1. Serum concentration of IL-17, IL-23 and TNF-α: detailed results in the psoriasis group and the control group
Parameter IL-17 assay results [pg/ml] IL-23 assay results [pg/ml] TNF-α assay results [pg/ml]
PsO Control group PsO Control group PsO Control group
Valid observations 60 30 60 30 60 30
Mean value 2.56 2.07 8.33 3.13 1.98 1.13
Median 1.88 1.56 8.12 3.01 1.77 1.02
Minimum value 1.75 1.39 5.36 4.66 1.59 0.97
Maximum value 3.37 2.77 10.31 1.77 2.36 1.33
Lower quartile 2.13 1.70 6.61 2.42 1.79 1.04
Upper quartile 2.98 2.42 9.11 3.88 2.18 1.22
Standard deviation 3.15 4.23 7.83 3.11 1.50 0.42
Statistical significance  
(Mann-Whitney U test)
p = 0.52 p = 0.0011 p = 0.032
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Figure 2. Serum levels of IL-17, IL-23 and TNF-α in patients 
with metabolic syndrome accompanying psoriasis in com-
parison to patients with psoriasis without the features of 
this syndrome. Mann-Whitney U test was performed to 
evaluate differences between the control and study groups. 
Median, lower and upper quartiles 25–75%, min.–max. of 
range are presented
Table 2. Serum levels of IL-17, IL-23 and TNF-α: detailed results in patients with metabolic syndrome accompanying 
psoriasis in comparison to patients with psoriasis without the features of this syndrome 
Parameter IL-17 assay results [pg/ml] IL-23 assay results [pg/ml] TNF-α assay results [pg/ml]
Ps + MS Ps/no MS Ps + MS Ps/no MS Ps + MS Ps/no MS
Valid observations 30 30 30 30 30 30
Mean value 4.05 2.09 8.12 8.25 2.42 1.83
Median 3.65 1.86 5.12 6.37 1.89 1.13
Minimum value 1.10 1.71 2.10 5.25 1.44 1.47
Maximum value 7.03 2.61 14.02 11.41 2.93 3.40
Lower quartile 2.58 1.88 5.07 6.90 1.92 1.93
Upper quartile 5.62 2.36 11.29 9.94 2.92 1.92
Statistical significance 
(Mann-Whitney U test)
p = 0.0001 p = 0.41 p = 0.42
Advances in Dermatology and Allergology 4, August / 2018364
Magdalena Pirowska, Aleksander Obtułowicz, Sylwia Lipko-Godlewska, Anna Goździalska, Katarzyna Podolec, Anna Wojas-Pelc
Table 3. Levels of IL-17 and IL-23: detailed results of patients with psoriatic arthritis (PsA) in comparison to psoriasis 
(PsO)
Parameter IL-17 assay results [pg/ml] IL-23 assay results [pg/ml]
PsO PsA PsO PsA
Valid observations 26 34 26 34
Mean value 2.11 3.88 6.35 14.03
Median 1.88 2.73 2.12 4.31
Minimum value 1.55 1.19 4.00 6.62
Maximum value 2.65 6.58 8.89 21.36
Lower quartile 1.84 2.50 5.19 10.19
Upper quartile 2.41 5.28 7.36 19.91
Standard deviation 1.82 5.38 7.89 14.63
Statistical significance (Mann-Whitney U test) p = 0.059 p = 0.0038
Figure 3. Level of IL-17 and IL-23 in sera of patients with psoriatic arthritis (PsA) in comparison to psoriasis (PsO). Mann-
Whitney U test was performed to evaluate differences between the control and study groups. Median, lower and upper 
quartiles 25–75%, min.–max. of range are presented
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the waist circumference and cytokines were similar: 
TNF-α (r = 0.15, p = 0.26) and IL-17 (r = 0.09, p = 0.50) 
IL-23 (r = –0.06, p = 0.66). Among the patients with pso-
riasis and psoriatic arthritis, no correlation was observed 
between PASI and the body mass, waist circumference 
and BMI. 
A higher level of IL-23 was found in sera of patients 
with psoriatic arthritis in comparison to normal psoria-
sis (PsO 6.35 ±7.89 vs. PsA 14.03 ±14.63; p < 0.05), no 
positive correlation of IL-17 in these groups was observed 
(PsO 2.11 ±1.82 vs. PsA 3.88 ±5.38; p = 0.059) (Figure 3, 
Table 3). Among the patients with psoriatic arthritis, no 
higher incidence of overweight and obesity was observed 
than for patients with normal psoriasis (BMI 27.7 ±5.68 
vs. 28.1 ±5.22 kg/m2).
Discussion
Previous studies show that in the pathogenesis of 
psoriasis, a special role is played by subpopulations of Th 
lymphocytes and dendritic cells together with cytokines 
produced by them: Th1 produce IFN-γ and IL-4 and IL-10, 
Th17 – IL-17 and IL-22, while Th22 – IL-22 and cytotoxic 
epithelial lymphocytes T CD8+ [12]. On the other hand, 
the Th17/IL-23 axis is crucial in maintaining the chronic 
inflammation, characteristic of the described dermato-
sis [13]. Interlekin-23, produced by dendritic cells, is a key 
cytokine taking part in autoimmunisation as it induces 
reproduction and maturation of Th17 cells. The studies 
performed confirmed increased levels of IL-23 and TNF-α 
in the blood of patients with psoriasis in comparison to 
the control group.
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It is assumed that in the pathogenesis of the ath-
erosclerotic plaque, a role is played by many cytokines: 
TNF-α, IL-1, IL-6, IL-18, IL-33, IL-37, and also, important in 
the course of psoriasis, IL-12, IL-23 and IL-17 [14]. In the 
recent scientific reports, the prevailing theory has been 
the generation of the atherosclerotic plaque by chronic 
inflammation in the course of diseases such as rheuma-
toid arthritis or psoriasis. In the results obtained in the 
study, the patients with metabolic syndrome accompany-
ing psoriasis had a higher level of studied cytokines than 
patients with the dermatosis only. The described results 
could have an important influence on the choice of the 
early method for patient treatment. Current reports point 
out the reduction of the risk of cardiovascular diseases 
and the reduction in glycemia and insulin resistance 
in patients treated with TNF-α inhibitors [15–17]. How-
ever, there are also studies showing an increase in the 
incidence of heart insufficiency and lipid disturbances in 
a similar group of patients [18, 19]. Similarly inconsistent 
reports refer to the anti-IL-12/23 therapy [20]. However, 
there are no studies on the influence of anti-IL-17 drugs 
on the risk of development of the features of meta-
bolic syndrome and cardiovascular diseases [16]. In the 
obtained results, the level of IL-17 was statistically sig-
nificantly higher in the group of patients with metabolic 
syndrome accompanying psoriasis, which could indicate 
the influence of drugs from the anti-IL17 group not only 
on the dermatosis, but also on metabolic disturbances 
and cardiovascular incidents. The results seem especially 
significant in the context of the control group, where no 
increased level of IL-17 was found in patients with meta-
bolic syndrome. Maybe IL-17 has a special influence on 
the occurrence of features of metabolic syndrome specifi-
cally in patients with psoriasis. 
In the performed study, only a weak correlation of the 
intensity of the disease with the concentration of TNF-α 
was confirmed, not significant statistically. Similar results 
were obtained by other authors [21, 22]. However, there 
are reports confirming a strong correlation between the 
intensity of the disease and TNF-α [23]. No correlation 
was shown between IL-17 and PASI. Similar results of 
studies, referring to the same cytokines, were obtained 
by Kyriakou et al. and by El-Moaty-Zaher et al. [24]. On 
the other hand, Michalak-Stoma et al. and Arican et al. 
confirmed a positive correlation between the intensity of 
psoriasis and the level of IL-17 [25, 26].
It is assumed that obesity is related to persisting, 
chronic inflammation of a low degree [27].
In the studied group of patients, no strong positive 
correlation was observed between the level of IL-17 and 
TNF-α and the obesity expressed as the BMI or waist cir-
cumference. The relation between the anti-TNF-α treat-
ment and the obesity is unclear. There are many works 
referring to the increase in body mass during the therapy 
[28–30]. Studies on mice showed that the deficiency of 
IL-17 increases the risk of diet-related obesity and accel-
erates the accumulation of fat tissue even in animals on 
low-fat diet [11]. Giovanni et al. proved an indirect influ-
ence of IL-17 on the presence of early atherosclerosis in 
obese patients [31]. A negative correlation was observed 
between the level of IL-23 and the obesity. Similar re-
sults were obtained by Owczarczyk-Saczonek et al., in 
the group of patients treated with anti-IL12/23, studied 
by them, an increase in body mass and BMI was found 
during the therapy [32, 33].
In the study, a higher level of IL-17 and IL-23 was 
also shown, in patients with psoriatic arthritis in com-
parison to patients with normal psoriasis. Despite the 
presence of many works studying the level of cytokines 
in the course of the described diseases, there are no 
comparative publications for both groups of patients, 
taking into account the above cytokines. The effective-
ness of anti-IL12/23 drugs in psoriatic arthritis is a con-
firmation of the obtained results of the studies. Addi-
tionally, the increased level of IL-17, both in patients 
with metabolic syndrome and with PsA, could indirectly 
indicate an increased cardiovascular risk in patients 
with affected joints in comparison to psoriasis affect-
ing only the skin. 
Conclusions
A lot of scientific research from recent years showed 
a connection between psoriasis and metabolic syndrome. 
Both nosological entities are accompanied by an increase 
in the level of proinflammatory cytokines, hyperuricemia, 
and abnormalities in excreted adipokines [7]. An accurate 
mechanism explaining the relation between the psoriasis 
and metabolic disorders is still not known, that is why 
further studies, evaluating the risk of co-incidence of the 
above entities, are necessary. The results of such works 
might lead to changes in therapy options and improve 
the results of psoriasis treatment.
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